

Virus detail

Virus name: hCoV-19/Denmark/DCGC-281349/2021

Accession ID: EPI_ISL_8002210

Type: betacoronavirus

Clade: GRA

Pango Lineage: BA.2 (Pango v.3.1.17 2022-01-05), Omicron (BA.2-like) (Scorpio)

AA Substitutions: Spike D405N, Spike D614G, Spike D796Y, Spike E484A, Spike G142D, Spike G339D, Spike H655Y, Spike

K417N, Spike N440K, Spike N501Y, Spike N679K, Spike N764K, Spike N969K, Spike P681H, Spike Q493R, Spike Q498R, Spike Q954H, Spike R408S, Spike S371F, Spike S373P, Spike S375F, Spike S477N, Spike T19I, Spike T376A, Spike T478K, Spike V213G, Spike Y505H, E T9I, M A63T, M Q19Z, N E31del, N G204R, N P13L, N R32del, N R203K, N S33del, N S413R, NS3 T223I, NSP1 S135R, NSP3 G489S, NSP3 T24I, NSP4 L264F, NSP4 L438F, NSP4 T327I, NSP4 T492I, NSP5 P132H, NSP12 P323L, NSP13 R392C, NSP14 I42V, NSP15 T112I

Variant: VOC Omicron GRA (B.1.1.529+BA.*) first detected in Botswana/Hong Kong/South Africa

Passage details/history: Original

Sample information

Collection date: 2021-12-10

Location: Europe / Denmark / Hovedstaden

Host: Human

Additional location information:

Gender: unknown
Patient age: unknown
Patient status: unknown

Specimen source:

Additional host information: n_infections=1

Sampling strategy:

Outbreak: Last vaccinated: Treatment:

Sequencing technology: Illumina

Assembly method: ARTIC-ncov2019 v1.1.0

Coverage:

Comment: Gap of 9 nucleotides when compared to the reference WIV04 sequence.

Institute information

Originating lab: Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark

Address: Artillerivej 5, 2300 Copenhagen S, Denmark

Sample ID given by the originating laboratory:

Submitting lab: Statens Serum Institut Bioinformatics and Microbial Genomics

Address: Artillerivej 2300 Copenhagen Denmark

Sample ID given by the submitting laboratory: hCoV-19/Denmark/DCGC-281349/2021

Authors: Danish Covid-19 Genome Consortium

Submitter information

Submitter: Matusevicius, Povilas

Submission Date: 2021-12-23

Address: Artillerivej 2300 Copenhagen Denmark

Important note: In the GISAID EpiFluTM Database Access Agreement, you have accepted certain terms and conditions for viewing and using data regarding influenza viruses. To the extent the Database contains data relating to non-influenza viruses, the viewing and use of these data is subject to the same terms and conditions, and by viewing or using such data you agree to be bound by the terms of the GISAID EpiFluTM Database Access Agreement in respect of such data in the same manner as if they were data relating to influenza viruses.